Seneca Biopharma, Inc. 2019 Form 10-K Summary
Filing identity: The supplied filing identifies the registrant as Seneca Biopharma, Inc. (formerly Neuralstem, Inc.), not Palisade Bio, Inc. It reports the fiscal year ended December 31, 2019; the filing was dated March 27, 2020.
Business context and reporting period
Seneca is a clinical-stage biopharmaceutical company developing neural stem-cell and small-molecule therapies. Its principal programs are NSI-566 for ALS, ischemic stroke and chronic spinal cord injury, and NSI-189 for major depressive disorder and other potential neurological indications. In 2019, the Company began emphasizing out-licensing its existing programs and pursuing in-licensing or acquisition of additional therapeutics.
- The Company changed its name from Neuralstem, Inc. to Seneca Biopharma, Inc. in October 2019.
- NSI-566 clinical programs remained in development, including a 22-subject, non-GCP Phase 2 ischemic-stroke study; the final subject’s final visit was expected in August 2020.
- NSI-189’s Phase 2 major-depressive-disorder study did not meet its primary efficacy endpoint, although certain secondary and cognitive measures showed statistically significant improvements.
- The Company had five full-time employees as of February 29, 2020 and relies substantially on consultants, contract manufacturers, clinical sites and other third parties.
Financial performance and liquidity
| Metric | 2019 | 2018 | Change |
|---|---|---|---|
| Revenue | $15,394 | $260,000 | Down $244,606 |
| Research and development expense | $4.06 million | $3.96 million | Up 3% |
| General and administrative expense | $4.59 million | $4.56 million | Up 1% |
| Total operating expenses | $8.65 million | $8.52 million | Up 1% |
| Operating loss | $8.63 million | $8.26 million | Worsened $372,238 |
| Other income, net | $280,043 | $3.33 million | Down substantially |
| Net loss | $8.35 million | $4.92 million | Worsened $3.43 million |
| Net loss per share | $3.80 | $7.54 | Improved on a per-share basis due largely to a higher share count |
| Cash used in operating activities | $7.26 million | $7.69 million | Improved $436,739 |
| Cash and cash equivalents at year-end | $5.11 million | $5.79 million | Down $672,193 |
- 2019 revenue consisted primarily of approximately $10,000 in ongoing intellectual-property license fees; the 2018 comparison included a $250,000 settlement-related milestone royalty. The Company generated no product-sale revenue.
- The 2019 net loss included a $499,138 non-cash gain from the change in fair value of liability-classified warrants and a $362,176 write-off or allowance related to a related-party receivable.
- Year-end working capital was approximately $4.4 million and stockholders’ equity was approximately $5.1 million. Accumulated deficit was approximately $222.0 million.
- Total liabilities were $1.46 million, including $264,665 of short-term notes and other current liabilities, $84,596 of warrant liabilities and $148,543 of long-term lease liabilities. The filing does not indicate material conventional long-term debt.
- Financing activities generated $6.59 million in 2019, primarily from the July 2019 equity and warrant offering, which produced approximately $6.6 million in net proceeds.
- There were no investing cash flows in 2019. In 2018, investing cash inflows were approximately $5.0 million from maturing short-term investments.
Material changes versus the prior comparable period
- Revenue declined sharply because 2018 included a $250,000 milestone-based royalty that did not recur.
- Net loss increased from $4.92 million to $8.35 million, principally because the 2018 results benefited from a $3.27 million non-cash warrant revaluation gain, compared with a $499,000 gain in 2019.
- Research and development spending increased modestly as the Company evaluated potential acquisitions and in-licensing opportunities, partly offset by lower clinical-trial spending as certain stem-cell activities were wound down.
- The common-share count increased materially following the July 2019 financing, warrant exercises and conversion of preferred stock. A 1-for-20 reverse stock split became effective July 17, 2019.
- The Company reduced its development activities and shifted toward maintaining existing programs while seeking partners and evaluating new assets.
Guidance, outlook, risks and unusual items
- Management expected research and development expenses to decrease as it sought partners for NSI-566 and NSI-189, but spending could increase if new assets were successfully acquired or licensed.
- Management stated that year-end cash, together with approximately $6.8 million of net proceeds from a January 2020 warrant-inducement transaction, was expected to fund operations for more than 12 months after filing.
- The independent auditor nevertheless expressed substantial doubt about the Company’s ability to continue as a going concern. Management stated that additional capital would be required for operations, clinical development and its acquisition strategy.
- In January 2020, holders exercised warrants for 5,555,554 common shares at $1.36 per share, generating approximately $7.6 million of gross proceeds. Replacement warrants for the same number of shares were issued at $1.23 per share, creating substantial potential dilution.
- The planned QYuns Therapeutics licensing transaction announced in October 2019 did not proceed; the Company disclosed in January 2020 that no definitive agreement would be completed.
- The Company has not obtained regulatory approval for any product candidate and does not expect significant product revenue in the near term, if ever.
- Key risks include recurring losses, dependence on additional financing, clinical-trial failure or delay, regulatory uncertainty, reliance on third-party manufacturers and clinical operators, intellectual-property challenges, competition, stock-price volatility and potential Nasdaq minimum-bid-price compliance issues.
- The Company identified the COVID-19 outbreak that began in late 2019 as a potential source of disruption to clinical sites, suppliers, research activities and business-development efforts.
Most important facts for investors to verify
- Confirm the issuer identity: the supplied filing is for Seneca Biopharma, Inc., not Palisade Bio, Inc.
- Verify the auditor’s going-concern language and the Company’s projected cash runway after the January 2020 financing.
- Review the January 2020 warrant inducement, replacement warrants and resulting dilution relative to the 9,428,011 shares outstanding reported in March 2020.
- Assess the status, data quality and regulatory usefulness of the non-GCP ischemic-stroke study and the other NSI-566 programs.
- Evaluate whether the Company can identify partners or complete an in-license or acquisition transaction after the failed QYuns arrangement.
- Reconcile the reported revenue decline, non-cash warrant gains and related-party receivable write-off when assessing operating performance.
- Review Nasdaq listing compliance, future financing needs, outstanding warrants, preferred-stock conversion rights and other potential sources of dilution.